Core Capabilities
The laboratory develops and applies state-of-the-art analytical technologies—primarily mass spectrometry, and liquid chromatography—to advance the understanding of cellular function at the protein, proteomic, metabolite, and metabolomic levels.
Effective August 31, 2025, the Protein Characterization Core in Frederick will discontinue all routine metabolomics services, including global metabolomic analysis. Requests for routine metabolomics support should be directed to the NIH Metabolomics Consortium (NIH-MC), which includes: Targeted Metabolomics (Biocrates Assay), Bile Acids, Short Chain Fatty Acids, Targeted Lipodomics, Untargeted Metabolomics.
Our Mission
The PCL offers various technologies to CCR investigators for the characterization of proteins and metabolites. The laboratory develops and applies state-of-the-art analytical technologies, primarily mass spectrometry and liquid chromatography, to advance the understanding of cellular function at the protein and metabolite levels. The PCL engages in both short- and long-term collaborations based on the need of each project. The PCL is operated by Leidos Biomedical Research Inc. on behalf of NCI as part of the Frederick National Laboratory.
For Service Requests
To request services from this CCR dedicated core facility, you must submit your requisition through NAS.